First published by GroundUp
Currently the standard of care for people with HIV starting treatment in South Africa, and many other countries, is a once-daily pill containing three drugs: tenofovir, emtricitabine (better known as FTC) and efavirenz.
Efavirenz is currently taken at a dose of 600mg per day, but research shows it can be taken at 400mg per day.
Dolutegravir is a new drug. It was recently approved in the US and Europe. It was approved in South Africa a few weeks ago and is expected to be available in the private sector in June or July. Dolutegravir has been shown to be better at suppressing HIV than efavirenz, and is ultimately expected to replace efavirenz in the standard drug regimen for new patients. Many patients also report psychological side effects with efavirenz, such as bad dreams and anxiety that are not reported with dolutegravir.
A new version of tenofovir, known by the scientific name tenofovir alafenamide fumarate as opposed to the current tenofovir disoproxil fumarate, requires a much lower dose and is much cheaper to mass produce. The popular abbreviation for the new version is TAF. It is at an advanced stage of development and, in contrast to dolutegravir and low-dose efavirenz which could be available in South Africa soon, it is likely still be a couple of years before TAF reaches patients here.
Eventually it is likely there will be a new once-daily pill containing TAF, FTC and dolutegravir.
At CROI, Vineet Prabhu and his colleagues at the Clinton Health Access Initiative (CHAI) presented findings on how the new drugs could save money for treatment programmes across the world.
They estimated that the lower-dose version of efavirenz would reach 25% of market share in 2021, and then dolutegravir would take over. Of the $3-billion in savings to programmes, the bulk, $1.8-billion, comes from the introduction of TAF.
The introduction of these drugs, besides being better for patients, will enable programmes to put more people on treatment.
Prabhu said that these findings support efforts to make these products available as soon as possible. He also stressed that a commitment by countries to adopting these new drugs would encourage more generic manufacturers to produce larger volumes at competitive prices. DM
Dolutegravir-based combination that includes the ARVs abacavir and lamivudine.
In other news...
South Africa is in a very real battle. A political fight where terms such as truth and democracy can seem more of a suggestion as opposed to a necessity.
On one side of the battle are those openly willing to undermine the sovereignty of a democratic society, completely disregarding the weight and power of the oaths declared when they took office. If their mission was to decrease society’s trust in government - mission accomplished.
And on the other side are those who believe in the ethos of a country whose constitution was once declared the most progressive in the world. The hope that truth, justice and accountability in politics, business and society is not simply fairy tale dust sprinkled in great electoral speeches; but rather a cause that needs to be intentionally acted upon every day.
However, it would be an offensive oversight not to acknowledge that right there on the front lines, alongside whistleblowers and civil society, stand the journalists. Armed with only their determination to inform society and defend the truth, caught in the crossfire of shots fired from both sides.
If you believe in supporting the cause and the work of Daily Maverick then take your position on the battleground and sign up to Maverick Insider today.
For whatever amount you choose, you can support Daily Maverick and it only takes a minute.
Scotland has a town called Dull. Oregon has a town called Boring and Australia a town called Boring. Combined they are coined the "Trinity of Tedium".